This module focuses on enhancing organizational capacity and provider readiness to treat opioid use disorder with buprenorphine-naloxone through reviewing how to recognize and diagnose OUD and differing treatment methodologies.

This module will describe: the epidemiology of opioid use disorder (OUD) and its impact on infectious disease epidemics in the United States, the use of medication treatment for OUD, and considerations for the management of infectious disease and OUD treatment.

This module will explore treatment considerations for patients who are using stimulants and participating in treatment for opioid use disorder.

This module will review the barriers to, and models for medications for OUD implementation, screening, brief intervention, and referral to treatment models of care, and collaborative care as a way of expanding medications for OUD. 

This module provides learners with an overview of the state of opioid use and opioid use disorder across the country and within the District of Columbia. The module will discuss the burden of opioid use disorders and overdoses and review current and historical trends in the epidemiological data.

This module will review the 2018 CDC Guidelines for Prescribing Opioids for Chronic Pain. The module presents clinical takeaways associated with the information in the Guidelines. The module will address strategies for utilizing the Guidelines in practice when initiating, dosing, selecting, continuing, and discontinuing opioids for chronic pain.

This module will provide learners with an increased understanding of mechanisms of pain and current best practices for treating acute pain. It will discuss the effectiveness and side effects of common pain medications, assisting providers to safely and effectively treat acute pain with non-opioid medications.

This module details effective patient-provider communication in addressing opioid use, misuse, and abuse. It identifies and describes models of communication, applying relevant content to the process of addressing opioid use disorders and the concern of stigma in clinical practice.

This module is intended for public use. By completing this module, learners will be able to utilize nasal naloxone to reverse a known overdose in emergency situations. Learners will understand how nasal naloxone reverses an overdose and will be able to summarize the epidemiology of opioid overdoses in the District of Columbia.

This module identifies and discusses relevant harm reduction techniques for people who use opioids, including people who use injectable drugs. The module will address how to hold patient-centered clinical conversations, incorporating harm reduction techniques. These strategies are then applied to a case study.

This module is intended for health professionals who have not received a DATA Waiver for buprenorphine. The module will explore introductory information on opioid use disorder as a chronic disease, the functioning of medications for opioid use disorder, and a path towards receiving a buprenorphine waiver, when applicable.

This module is intended for providers who have obtained their DATA Waiver to prescribe buprenorphine. The module addresses the difficulties that providers face in treating patients with opioid use disorders with buprenorphine and assist providers in working with patients on unanticipated events such as injury and pregnancy. The module aims to increase the confidence of DATA Waived providers in treating patients with buprenorphine in difficult cases.

This module reviews the impact of diet and chronic illness on pain. It assists providers by improving their ability to discuss various evidence-based diets that can help to alleviate pain.

This module introduces two non-pharmacological approaches for addressing pain: CBT and mind-body techniques. These techniques are examined for effectiveness and explored in depth to enable learners to utilize these approaches in practice.

This module examines three related non-pharmacological approaches to pain management. The module will discuss relevant benefits and risks associated with these therapies. Additionally, the module provides health professionals with the ability to integrate these approaches into their practice and knowledge of which patients are good candidates for these types of pain treatments.

This module summarizes the case of Mayo Clinic’s post-operative pain prescribing practices to highlight the development and implementation of prescribing guidelines by surgical area. The module addresses these developments within the context of the 2016 CDC Guidelines and the 2016 Minnesota draft guidelines for opioid prescribing. It explores the process of developing guidelines within the institution and this process’s effects on post-op prescribing.